SMC reject lecanemab for use in NHS in Scotland
The Scottish Medicines Consortium (SMC) has rejected new Alzheimer’s drug, lecanemab, for use in the NHS in Scotland. This aligns with the view of NICE (which we covered here: https://journalofdementiacare.co.uk/mhra-licence-lecanemab-for-use-in-the-uk) when considering lecanemab for use in the NHS in England and Wales. The reasons given by the SMC are similar to NICE. Anyone eligible for…